Mersana Competitors

Stocks . USA . 
Stock . Mersana Therapeutics
MRSN Stock  USD 0.52  0.02  4.00%   
Mersana Therapeutics competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Mersana Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mersana Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mersana Therapeutics Correlation with its peers.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Mersana Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mersana Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.030.609.76
Details
Intrinsic
Valuation
LowRealHigh
0.101.9511.11
Details

Mersana Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mersana Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mersana and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mersana Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
INZY
+ 0.92
TERN
ABOS
+ 0.88
TERN
HOOK
+ 0.85
AMLX
CGEM
+ 0.81
AMLX
INZY
+ 0.8
ABOS
DAWN
+ 0.77
ABOS
  
High negative correlations   
XFOR
- 0.08
ABOS
RLAY
- 0.0
THRX
CGEM
- 0.0
THRX
THRX
- 0.0
HOOK
THRX
- 0.0
DAWN
THRX
- 0.0
XFOR

Risk-Adjusted Indicators

There is a big difference between Mersana Stock performing well and Mersana Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mersana Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TERN  2.99 (0.56) 0.00 (0.52) 0.00 
 0.00 
 5.17 
(6.75)
 26.61 
AMLX  3.40 (0.78) 0.00 (0.84) 0.00 
 0.00 
 4.58 
(7.94)
 16.76 
ABOS  2.83 (0.80) 0.00 (0.65) 0.00 
 0.00 
 6.57 
(6.19)
 15.46 
INZY  4.01 (1.01) 0.00 (0.84) 0.00 
 0.00 
 7.72 
(8.61)
 38.13 
XFOR  7.45  0.71  0.09 (0.59) 7.25 
(11.43)
 26.42 
(13.51)
 68.45 
DAWN  2.08 (0.54) 0.00 (1.06) 0.00 
 0.00 
 3.82 
(3.81)
 22.86 
HOOK  3.38 (0.77) 0.00  1.58  0.00 
 0.00 
 6.37 
(7.39)
 32.80 
THRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CGEM  2.44 (0.68) 0.00 (1.78) 0.00 
 0.00 
 4.98 
(6.27)
 15.27 
RLAY  4.18 (0.36) 0.00 (0.26) 0.00 
 0.00 
 7.42 
(7.87)
 26.72 
All Fundamental Data

Mersana Therapeutics Competitive Analysis

The better you understand Mersana Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mersana Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mersana Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MRSN TERN AMLX ABOS INZY XFOR DAWN HOOK CGEM RLAY
 4.00 
 0.52 
Mersana
 1.86 
 3.69 
Terns
 3.80 
 3.28 
Amylyx
 1.59 
 1.28 
Acumen
 0.83 
 1.20 
Inozyme
 8.11 
 0.40 
XFOR
 4.03 
 9.06 
Day
 2.00 
 1.53 
Hookipa
 1.39 
 8.49 
Cullinan
 4.92 
 3.41 
Relay
Market Volatility
(90 Days Market Risk)
Extremely Dangerous
Slightly risky
Unstable
Unstable
Unstable
Out of control
Not too volatile
Relatively risky
Not too volatile
Moderately volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Average
Low
About Average
Very High
High
Average
Above Average
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Strong Sell
Sell
Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Sell
Current Ratio
3.32
23.59
7.96
37.21
14.54
2.39
31.45
5.48
10.04
15.22
Net Asset
226.06 M
268.52 M
517.45 M
310.12 M
200.85 M
147.26 M
582.79 M
161.34 M
484.18 M
871.3 M
Profit Margin
-2.14
N/A
-1.32
N/A
N/A
N/A
-0.73
-0.87
N/A
N/A
EBITDA
(166.08 M)
(102.27 M)
39.89 M
(51.61 M)
(74.81 M)
(107.1 M)
(217.27 M)
(77.34 M)
(190.34 M)
(372.47 M)
Operating Margin
-0.96
N/A
-181.88
N/A
N/A
-61.61
-2.24
-3.74
N/A
-38.54
Current Valuation
(59.01 M)
(58.05 M)
49.24 M
(95.27 M)
(7.09 M)
9.28 M
388.14 M
(38.72 M)
99.95 M
(155.6 M)
Price To Book
61.64
0.86
1.43
0.35
0.94
1.11
1.82
0.25
0.84
0.74
Retained Earnings
(826.36 M)
(332.63 M)
(304.95 M)
(222.8 M)
(285.93 M)
(477.9 M)
(554.08 M)
(369.26 M)
(200.86 M)
(1.74 B)
Current Asset
71.4 M
N/A
N/A
N/A
N/A
N/A
N/A
26.61 M
N/A
N/A
Beta
1.38
-0.36
-0.54
-0.006
1.29
0.12
-1.46
0.71
-0.16
1.62
Number Of Employees
123
66
384
51
59
143
181
151
85
15
Equity Positions Weight
N/A
N/A
50.03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
123.53 M
84.94 M
85.69 M
60.08 M
64.24 M
170.55 M
101.36 M
9.66 M
58.51 M
169.52 M
Cash Flow From Operations
(168.88 M)
(67.39 M)
11.92 M
(43.06 M)
(70.67 M)
(96.51 M)
(78.11 M)
(57.52 M)
(134.28 M)
(249.11 M)
Total Debt
33.83 M
603 K
4.24 M
28.49 M
46.59 M
58.28 M
2.6 M
6.56 M
3.59 M
48.5 M
Return On Equity
-2.8
-0.28
-0.84
-0.33
-0.79
-0.26
-0.22
-0.52
-0.27
-0.44
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.23
-0.19
-0.43
-0.21
-0.36
-0.47
-0.28
-0.21
-0.2
-0.28
Number Of Shares Shorted
9.15 M
5.92 M
3.38 M
1.74 M
4.3 M
11.06 M
17.5 M
84.09 K
8.77 M
15.79 M
Book Value Per Share
0.009
4.29
2.86
3.62
1.29
0.35
4.97
5.96
10.8
4.64
Current Liabilities
51.32 M
N/A
N/A
N/A
N/A
N/A
N/A
25.01 M
N/A
N/A
Total Asset
226.06 M
268.52 M
517.45 M
310.12 M
200.85 M
147.26 M
582.79 M
161.34 M
484.18 M
871.3 M
Debt To Equity
0.28
0.01
0.036
N/A
0.02
1.28
0.002
0.052
0.001
0.06
Short Ratio
1.37
3.29
3.55
5.69
4.98
1.75
17.27
1.43
19.21
7.93
Target Price
5.43
19.06
8.0
10.8
18.0
3.13
34.0
4.5
33.89
19.64
Shares Owned By Institutions
92.15
99.75
68.36
76.57
92.5
59.17
94.5
58.66
95.0
98.07
Market Capitalization
64.66 M
313.42 M
281.07 M
76.9 M
77.09 M
67.38 M
918.28 M
18.44 M
496.77 M
578.07 M
Price To Earning
-0.98
N/A
N/A
N/A
N/A
N/A
3.88
12.06
5.23
N/A
Price To Earnings To Growth
N/A
N/A
-0.15
-0.23
-0.06
N/A
N/A
-0.19
N/A
0.07
Price To Sales
1.86
302.64
1.43
538.78
N/A
60.0
7.0
0.37
26.88
57.77
Net Income
(171.67 M)
(90.21 M)
49.27 M
(52.37 M)
(71.17 M)
(101.17 M)
(95.5 M)
(81.58 M)
(153.16 M)
(337.71 M)
Earnings Per Share
-0.6
-1.18
-3.82
-1.38
-1.55
-0.08
-1.02
-3.67
-2.78
-2.36
Shares Owned By Insiders
1.5
0.25
11.39
11.23
1.3
1.27
16.94
2.0
5.0
1.93
Revenue
36.85 M
N/A
380.79 M
N/A
N/A
N/A
131.16 M
20.13 M
N/A
10.01 M
Working Capital
150.42 M
255.49 M
382.62 M
233.64 M
181.56 M
99.21 M
488.88 M
105.13 M
452.05 M
758.48 M
Cash And Equivalents
225.13 M
139.81 M
206.68 M
189.91 M
151.48 M
47.38 M
394.86 M
117.92 M
611 M
1.05 B
Cash Per Share
2.32
5.51
3.53
4.69
3.77
0.69
5.38
2.16
13.4
8.72
Gross Profit
(37.39 M)
1000 K
(99.82 M)
(43.56 M)
N/A
628 K
125.88 M
(25.3 M)
18.94 M
10.01 M
Day Typical Price
0.51
3.65
3.23
1.27
1.19
0.39
9.21
1.52
8.49
3.29
Accumulation Distribution
0.0943
0.0484
0.0576
0.0462
0.0492
0.1
0.0545
0.0764
0.0449
0.11
Market Facilitation Index
0.05
0.18
0.19
0.06
0.06
0.04
0.52
0.12
0.39
0.36
Daily Balance Of Power
0.4
(0.39)
0.6316
0.3333
(0.17)
0.75
(0.73)
0.25
(0.31)
0.4444
Period Momentum Indicator
0.02
(0.07)
0.12
0.02
(0.01)
0.03
(0.38)
0.03
(0.12)
0.16
Rate Of Daily Change
1.04
0.98
1.04
1.02
0.99
1.08
0.96
1.02
0.99
1.05
Day Median Price
0.51
3.63
3.21
1.27
1.19
0.38
9.28
1.51
8.49
3.23
Price Action Indicator
0.025
0.025
0.13
0.02
0.005
0.035
(0.41)
0.035
(0.06)
0.26
Relative Strength Index
32.36
33.12
34.62
33.22
32.59
45.1
43.12
35.84
29.9
40.22
Coefficient Of Variation
(464.95)
(731.26)
(525.04)
(448.57)
(583.43)
1618.51
(564.32)
(652.58)
(460.58)
(1,383)
Mean Deviation
6.11
2.99
3.4
2.83
4.01
7.45
2.08
3.38
2.44
4.18
Jensen Alpha
(1.93)
(0.56)
(0.78)
(0.80)
(1.01)
0.7058
(0.54)
(0.77)
(0.68)
(0.36)
Total Risk Alpha
(1.69)
(0.45)
(0.67)
(0.72)
(0.85)
1.11
(0.45)
(0.61)
(0.59)
(0.23)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
0.0862
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
77.2
N/A
N/A
N/A
N/A
Standard Deviation
9.16
4.18
4.13
3.69
5.98
12.05
3.03
4.89
3.13
5.3
Kurtosis
7.69
2.69
(0.61)
0.3886
6.31
6.89
10.97
3.2
0.7855
0.3598
Potential Upside
9.05
5.17
4.58
6.57
7.72
26.42
3.82
6.37
4.98
7.42
Treynor Ratio
(0.98)
(0.52)
(0.84)
(0.65)
(0.84)
(0.59)
(1.06)
1.58
(1.78)
(0.26)
Maximum Drawdown
53.67
26.61
16.76
15.46
38.13
68.45
22.86
32.8
15.27
26.72
Variance
83.93
17.5
17.08
13.65
35.76
145.22
9.18
23.88
9.82
28.14
Market Risk Adjusted Performance
(0.97)
(0.51)
(0.83)
(0.64)
(0.83)
(0.58)
(1.05)
1.59
(1.77)
(0.25)
Risk Adjusted Performance
(0.15)
(0.09)
(0.13)
(0.16)
(0.12)
0.0549
(0.12)
(0.10)
(0.15)
(0.04)
Skewness
(1.25)
(0.07)
(0.34)
0.5464
(1.35)
2.12
(1.96)
0.212
(0.06)
0.0659
Semi Deviation
N/A
N/A
N/A
N/A
N/A
7.25
N/A
N/A
N/A
N/A
Information Ratio
(0.21)
(0.13)
(0.19)
(0.22)
(0.17)
0.0629
(0.17)
(0.15)
(0.21)
(0.07)
Value At Risk
(13.89)
(6.75)
(7.94)
(6.19)
(8.61)
(13.51)
(3.81)
(7.39)
(6.27)
(7.87)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
(11.43)
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
8.79
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
52.54
N/A
N/A
N/A
N/A

Mersana Therapeutics Competition Performance Charts

Five steps to successful analysis of Mersana Therapeutics Competition

Mersana Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mersana Therapeutics in relation to its competition. Mersana Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mersana Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mersana Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mersana Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mersana Therapeutics position

In addition to having Mersana Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Staples ETFs Thematic Idea Now

Consumer Staples ETFs
Consumer Staples ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:
How To Invest In Mersana
Details
Is Mersana Stock a good investment?
Details
What is Mersana Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Mersana Therapeutics Correlation with its peers.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY